![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bbi Hldgs | LSE:BBI | London | Ordinary Share | GB00B00M4S16 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 185.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:7500X BBI Holdings PLC 05 June 2007 BBI Holdings plc Trading Update BBI Holdings Plc ("BBI"), the AIM listed developer and manufacturer of rapid result diagnostic tests and enzymes for the diagnostic industry, announces a trading update for the year ended 31 March 2007. After a year of significant corporate activity it is pleasing to report that the core business has demonstrated significant growth in sales and profits. The opportunities driven by market growth and the new acquisitions provide the basis for sustained growth for the business in the coming years. The business continues to develop its manufacturing business and I am pleased to announce that the trading results for the year ended 31 March 2007 are in line with market expectations with Turnover showing an overall increase for the year of 56%, of which acquisitions contributed 27% and organic growth 29%. Commenting, Julian Baines said, "As well as achieving results for the year in line with expectations, which has helped demonstrate the growth prospects for BBI, I am pleased to announce the signature of an additional manufacturing contract with a North American company that will further cement the growth in the current year. We are also in the early stages of the integration of Theratase into the Group and whilst it is clear initial infrastructural investment is required I am confident that this, over time, will yield further growth in this business in addition to the current growth of the BBI business." The preliminary results for the year ended 31 March 2007 will be announced on 30 July 2007. Contacts: For further information please contact: BBI Holdings plc Parkgreen Communications Ltd Julian Baines, Managing Director Paul McManus Tel: 029 2074 7232 Tel: 020 7479 7933 Mob: 07980 541 893 www.bbigold.com Email: paul.mcmanus@parkgreenmedia.com About BBI Holdings PLC (AIM: BBI): BBI is a leading supplier of products and services to the global diagnostic and healthcare industries. BBI floated on AIM on 28 April 2004 at 47p. BBI operates in three core areas: 1. BBInternational (diagnostics) Incorporating: British Biocell, Cardiff, UK BBI Dundee (formerly Alchemy Laboratories), Dundee, UK BBI Research, Madison, Wisconsin, USA Qnostics, Glasgow, UK BBI manufactures superior quality gold reagents which are used to bind with specific antibodies or antigens, which are used in diagnostic tests to provide a positive or negative visual signal. BBI also provides contract product development services for leading diagnostic companies using its expertise to develop rapid result diagnostic tests. BBI also manufactures rapid result diagnostic tests in the UK and the US. Rapid test manufacture involves placing conjugate onto a pad or strip and enclosing this within a preformed plastic package 'housing' designed to the customer's specifications. BBI's Qnostics division supplies molecular quality control reagents to the global market place. www.bbigold.com 2. BBI Enzymes Incorporating: Biozyme, Blaenavon, UK Seravac, Cape Town, S Africa. Theratase was acquired by BBI in May 2007 to form BBI's enzyme division. Biozyme and Seravac are leading manufacturers and suppliers of high quality specialist natural enzymes to the medical diagnostics industry. Enzymes are proteins which drive complex reactions that occur in all living organisms. Their high specificity and dramatic catalytic activity has been exploited within the diagnostic industry. www.theratase.com 3. BBI Healthcare (diabetes) Brands: GlucoGel SensoCard Plus GlucoTabs In April 2004 BBI acquired Hypostop (now renamed GlucoGel in the UK). GlucoGel is an easy to use dextrose gel which is included in the National Institute for Clinical Excellence's (NICE) treatment guideline for hypoglycaemia. BBI Healthcare was founded in April 2006 to manage the sales and marketing of GlucoGel, and build a diabetes care product portfolio. In July 2006 BBI acquired the UK's only talking blood glucose meter for the visually impaired called SensoCard Plus. The acquisition gives BBI exclusive distribution rights for within the UK, US, Canada and India. www.bbihealthcare.com This information is provided by RNS The company news service from the London Stock Exchange END TSTFIMFTMMAMBTR
1 Year Bbi Holdings Chart |
1 Month Bbi Holdings Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions